Balance Assessment in HCV Patients Taking (Sovaldi / Daklinza) Regimen

Abstract

epatitis C virus (HCV) infection is a major public health burden in Egypt, where it bears the highest prevalence rate in the world. So in recognition of the HCV tremendous health and economic burden the Egyptian government established The National Committee for Control of Viral Hepatitis to implement an integrated nationwide strategy to provide patient care by effective screening protocols and ensure global treatment access to every hepatitis C virus patient promoting sofosbuvir (Sovaldi) an inhibitor of the phosphoprotein (NS5B) as its primary treatment, with daclatasvir (Daklinza) an inhibitor of (NS5A) phosphoprotein in many regimens.